Reminder: Welcome to an Elekta R&D update at University Medical Center Utrecht

STOCKHOLM, January 13, 2015 – Elekta welcomes investors, analysts and
media to an update on its investments in R&D, with special attention to the
Atlantic project: a magnetic resonance imaging (MRI) guided radiation therapy
system.
This event will be held on Thursday, January 22, 2015, from 10:30–13:30 CET
at University Medical Center (UMC) Utrecht in the Netherlands. Note that due to
great interest, the presentation will be extended by one hour.

Jan Lagendijk, Professor and Head of Radiation Oncology, Radiology and Nuclear
Medicine Physics at UMC and Marco van Vulpen, Professor of Radiation Therapy and
MRI, also at UMC, will discuss the clinical relevance of MRI-guided radiation
therapy and show the world's first fully integrated research system, as it nears
completion at UMC.

Niklas Savander, Elekta’s President and CEO; Dee Mathieson, Senior Vice
President, Elekta Oncology; and Kevin Brown, Elekta’s Global Vice President
Scientific Research, will talk about Elekta's R&D investments in general as well
as the status of the project and the milestones to market introduction of the
MRI-guided linear accelerator in particular.

Investors, analysts and media who would like to attend, are kindly requested to
give notice by e-mail to elisabeth.natt.och.dag@elekta.com before January 15.

It will also be possible to listen to the presentations over the phone and via
the web. Please use the following link: http://elekta-rd.creo.se/

Telephone numbers:

Sweden: +46850556453
UK: +442030092455
US: +18552283719

Passcode: 644503#

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 17:15 CET on January 13, 2015.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.